Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.55 |
| ▸ | CTSD | P07339 | 2/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8155821 | 0.79 | BACE1 (0.41) | BACE1 | |
| SCHEMBL28133767 | 0.79 | GPR84 (0.38) | — | |
| SCHEMBL475723 | 0.77 | LCK (0.45) | BACE1 | |
| SCHEMBL4751790 | 0.75 | BACE1 (0.36) | BACE1 | |
| SCHEMBL27975645 | 0.73 | DAO (0.45) | — | |
| SCHEMBL14811147 | 0.71 | MRGPRX4 (0.40) | — | |
| SCHEMBL7864565 | 0.71 | LCK (0.40) | BACE1 | |
| SCHEMBL28138572 | 0.71 | DAO (0.48) | — | |
| SCHEMBL28139210 | 0.71 | CYP2C19 (0.43) | — | |
| SCHEMBL4749584 | 0.71 | BACE1 (0.44) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816387-B2 | β secretase inhibitor | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816387-B2 | β secretase inhibitor | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816387-B2 | β secretase inhibitor | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090198056-A1 | Beta secretase inhibitor | KISO, YOSHIAKI (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198056-A1 | Beta secretase inhibitor | KISO, YOSHIAKI (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198056-A1 | Beta secretase inhibitor | KISO, YOSHIAKI (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1942101-A1 | SECRETASE INHIBITOR | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198056-A1 | Beta secretase inhibitor | BACE1, BACE2, APP | BACE1 1/4885CTSD 75/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.